BCAX · Bicara Therapeutics Inc.

$24.92 +0.64 (+2.64%) At close · Aug 17

Market Cap

$1.61B

66.17M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Claire Mazumdar	Chief Executive Officer	$625,000	—	—	—	$292,188	$10,500	$927,688
Ryan Cohlhepp	Pharm.D. President and Chief Operating Officer	$588,000	$10,000	—	—	$249,900	$10,500	$858,400
David Raben	Chief Medical Officer The amounts reported represent the aggregate grant date fair value of stock option awards granted to our named executive officers during the applicable fiscal years, computed in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account any estimated forfeitures related to service-based vesting. A discussion of the assumptions used in determining grant date fair value may be found in Note 10 to our financial statements in our Annual Report on Form 10-K for the year ended December 31, 2025. These amounts do not correspond to the actual value that may be recognized by the named executive officers upon exercise of the applicable award or sale of the underlying shares of stock. The amounts reported for the fiscal year ended December 31, 2025 represent the annual bonuses each named executive officer earned under our annual cash bonus program based on achievement of company performance and individual performance during the applicable fiscal year, which were paid in the first quarter of fiscal year following the applicable fiscal year. The amounts reported represent employer profit sharing contributions and employer matching contributions earned by our named executive officers under our 401(k) plan during the applicable fiscal years. Dr. Raben was not a named executive officer for the fiscal year ended December 31, 2024.	$525,000	$5,000	—	—	$170,625	$8,539	$709,164

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Claire Mazumdar	Ph.D. M.B.A. Chief Executive Officer	$517,500	$287,000	—	$8,088,723	$10,000	$15,300	$8,918,523
Ryan Cohlhepp	Pharm.D. President and Chief Operating Officer	$517,500	$278,000	—	$3,641,839	$10,000	$20,250	$4,467,589
Ivan Hyep	M.B.A Chief Financial Officer	$438,125	$457,000	—	$2,683,461	—	$20,250	$3,598,836

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Claire Mazumdar	Ph.D. M.B.A. Chief Executive Officer	$450,000	$180,000	—	$3,893,323	$20,000	—	$4,543,323
Ryan Cohlhepp	Pharm.D. President and Chief Operating Officer	$450,000	$190,000	—	$2,498,786	$20,000	—	$3,158,786
Ivan Hyep	M.B.A Chief Financial Officer	$350,000	$247,500	—	$1,883,243	—	—	$2,480,743

Executive changes

Person	Role	Change	Effective	Filed
Jeremy Bender, Ph.D.	Class I director	Appointed	2026-07-28	2026-07-28
Kiran Mazumdar-Shaw	Board of Directors	Resigned	2026-07-28	2026-07-28

Key facts CIK 2023658 CUSIP 055477103 13F (30d) 171 filings 170 filers Visit website Investor relations